Clinical Trials
95 trialsBOLSTER
Lisata Therapeutics, Inc.
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
National Cancer Institute (NCI)
Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial)
National Cancer Institute (NCI)
panSOHO
Bayer
ANTARES
Instituto do Cancer do Estado de São Paulo
TRAP-BTC
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers
Seagen Inc.
Trifluridine/Tipiracil + Oxaliplatin in Participants With Advanced or Metastatic Biliary Tract Cancer
Case Comprehensive Cancer Center
TRANSFORM-GBC
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
A Study of Different Dosing Schedules of Selumetinib With Cisplatin/Gemcitabine (CIS/GEM) Versus CIS/GEM Alone in Biliary Cancer
University Health Network, Toronto
HERIZON-BTC-01
Jazz Pharmaceuticals
KEYVIBE-005
Merck Sharp & Dohme LLC
SAIB
First Affiliated Hospital of Zhejiang University
Testing A New Combination of Anti-cancer Immune Therapies, Atezolizumab and CDX-1127 (Varlilumab) With or Without the Addition of a Third Anti-cancer Drug, Cobimetinib, for Advanced-Stage Biliary Tract Cancer
National Cancer Institute (NCI)
GALENT-BT
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Immunotherapy With Durva and Treme With or Without Capecitabine in Adjuvant Treatment for Biliary Tract Cancer
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
Elevation Oncology
Camrelizumab and Chemotherapy With or Without Anlotinib as First-line Treatment for Advanced Gallbladder Cancer and Extrahepatic Cholangiocarcinoma
The First Affiliated Hospital of Zhengzhou University
GOLD-HAIC
Tianjin Medical University Cancer Institute and Hospital
DEBATE
Asan Medical Center
Toripalimab Combined With Capecitabine as Postoperative Adjuvant Therapy for Patients With Resectable Advanced Extrahepatic Biliary Tract Cancer
Tianjin Medical University Cancer Institute and Hospital
Target Therapy With GEMOX in Recectable Gallbladder Carcinoma Patients Monitored by ctDNA
Shanghai Jiao Tong University School of Medicine
Study of Irinotecan Liposome Injection in Patients With Advanced Biliary Tract Cancer
CSPC Ouyi Pharmaceutical Co., Ltd.
Atezolizumab With or Without Cobimetinib in Treating Patients With Metastatic Bile Duct Cancer That Cannot Be Removed by Surgery or Gallbladder Cancer
National Cancer Institute (NCI)
Combination Therapy of HAIC, Surufatinib and Tislelizumab for Unresectable or Metastatic Biliary Tract Cancer
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Pembrolizumab in Biliary Tract Cancer
European Organisation for Research and Treatment of Cancer - EORTC
M7824 Monotherapy in Locally Advanced or Metastatic Second Line (2L) Biliary Tract Cancer (Cholangiocarcinoma and Gallbladder Cancer)
EMD Serono
Envafolimab Combined With GEMOX in First-line Treatment of Advanced GBC
Eastern Hepatobiliary Surgery Hospital
Trifluridine/Tipiracil and Irinotecan for the Treatment of Advanced Refractory Biliary Tract Cancer
Mayo Clinic
TAS-102 in Treating Advanced Biliary Tract Cancers
Mayo Clinic
Ramucirumab in Treating Patients With Advanced or Metastatic, Previously Treated Biliary Cancers That Cannot Be Removed by Surgery
M.D. Anderson Cancer Center
IMMUCHEC
AIO-Studien-gGmbH
A Study of STI-3031 (an Anti-PD-L1 Antibody) in Patients With Selected Relapsed/Refractory Malignancies
Sorrento Therapeutics, Inc.
Toripalimab Plus Lenvatinib as Second-line Treatment in Advanced Biliary Tract Cancers
Peking Union Medical College Hospital
Combination of Gemcitabine, Albumin-paclitaxel , Sintilimab and Bevacizumab in Unresectable Gallbladder Cancer
Fudan University
Tislelizumab Combined With Lenvatinib and GEMOX Versus Tislelizumab Combined With GEMOX in Conversion Therapy of ICC and GBC.
Tianjin Medical University Cancer Institute and Hospital
Comparing the Current Hydration Regimen for the ABC02 Chemotherapy Regimen Versus a Shorter Hydration
Imperial College Healthcare NHS Trust
Gemcitabine Hydrochloride, Cisplatin, and Nab-Paclitaxel in Treating Patients With Advanced or Metastatic Biliary Cancers
M.D. Anderson Cancer Center
Pembrolizumab, a Monoclonal Antibody Against PD-1, in Combination With Capecitabine and Oxaliplatin (CAPOX) in People With Advanced Biliary Tract Carcinoma (BTC)
National Institutes of Health Clinical Center (CC)
Single Agent Regorafenib in Refractory Advanced Biliary Cancers
H. Lee Moffitt Cancer Center and Research Institute
Copanlisib (BAY 80-6946) in Combination With Gemcitabine and Cisplatin in Advanced Cholangiocarcinoma
H. Lee Moffitt Cancer Center and Research Institute
Varlitinib Plus Capecitabine in Chinese Patients With Advanced or Metastatic Biliary Tract Cancer
ASLAN Pharmaceuticals
ACCORD
Sun Yat-sen University
PRIORITY
Asan Medical Center
Trastuzumab in Treating Patients With Locally Advanced or Metastatic Gallbladder Cancer or Bile Duct Cancer That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
A Phase 2 Trial of Regorafenib as A Single Agent in Advanced and Metastatic Biliary Tract Carcinoma/Cholangiocarcinoma Patients Who Have Failed First-line Chemotherapy
University of Pittsburgh
Chemothetapy FORFIRINOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma
Shanghai Jiao Tong University School of Medicine
Molecularly Target Therapy With FORFIRINOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma
Shanghai Jiao Tong University School of Medicine
Clinical Trial to Investigate the Efficacy of Treatment With Gemcitabine/Pazopanib in Patients With Biliary Tree Cancer
Hellenic Cooperative Oncology Group
Apapitatin Combined With SOX for Palliative Adjuvant Chemotherapy in Patients With Advanced Gallbladder Carcinoma
Eastern Hepatobiliary Surgery Hospital